Our top pick for
Building a portfolio
Leap Therapeutics, Inc is a biotechnology business based in the US. Leap Therapeutics shares (LPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Leap Therapeutics employs 30 staff and has a trailing 12-month revenue of around USD$1.5 million.
|52-week range||USD$1.43 - USD$3.24|
|50-day moving average||USD$2.2641|
|200-day moving average||USD$2.1159|
|Wall St. target price||USD$5.3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.663|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Leap Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Leap Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Leap Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Leap Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$1.5 million|
|Gross profit TTM||USD$1.5 million|
|Return on assets TTM||-57.24%|
|Return on equity TTM||-122.55%|
|Market capitalisation||USD$109.2 million|
TTM: trailing 12 months
There are currently 1.4 million Leap Therapeutics shares held short by investors – that's known as Leap Therapeutics's "short interest". This figure is 16.5% up from 1.2 million last month.
There are a few different ways that this level of interest in shorting Leap Therapeutics shares can be evaluated.
Leap Therapeutics's "short interest ratio" (SIR) is the quantity of Leap Therapeutics shares currently shorted divided by the average quantity of Leap Therapeutics shares traded daily (recently around 715724.62311558). Leap Therapeutics's SIR currently stands at 1.99. In other words for every 100,000 Leap Therapeutics shares traded daily on the market, roughly 1990 shares are currently held short.
However Leap Therapeutics's short interest can also be evaluated against the total number of Leap Therapeutics shares, or, against the total number of tradable Leap Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Leap Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Leap Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0347% of the tradable shares (for every 100,000 tradable Leap Therapeutics shares, roughly 35 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Leap Therapeutics.
Find out more about how you can short Leap Therapeutics stock.
We're not expecting Leap Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Leap Therapeutics's shares have ranged in value from as little as $1.43 up to $3.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Leap Therapeutics's is 1.2771. This would suggest that Leap Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.